GW1516 (also known as Cardarine, Endurobol, and GW501516) it is a selective agonist of peroxisome proliferator-activator receptors (PPARs), not a steroid. It was originally developed for the treatment of obesity, diabetes mellitus, dyslipidemia, and cardiovascular diseases. GW1516 activates adenosine monophosphate-activated protein kinase (an enzyme involved in energy processes in our body also known as AMPK) and thus stimulates glucose uptake in skeletal muscle tissue. In studies, GW1516 demonstrated the ability to reverse the metabolic disorder in obese men with prediabetes syndrome, most likely by stimulating fatty acid oxidation. GW1516 has shown muscular protective and enhancing effects, and this seems to be related to a decrease in muscle inflammation and damage. GW1516 has been shown to elicit cardiovascular protection, possibly due to its actions in decreasing insulin spikes and stabilizing cholesterol levels. It is notable that GW1516 does not simply decrease very low-density lipoproteins (VLDL) but also increases high-density lipoproteins (HDL), which is the result of GW1516 increasing utilization of the cholesterol transporter ABCA1. The two main uses of GW1516 in sports are to increase muscular endurance and enhance fat loss to improve body composition.